GlassScriptPhysician profile
Thomas Augustine Franco
NPI 1700949880
$1,609.81
in general payments reported to CMS, 2019-2025
27 companies · $404 in 2025
The $404 reported for 2025 was more than what 75% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.88 · 2020: $34.14 · 2021: $293 · 2022: $294 · 2023: $271 · 2024: $282 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.52 | 2022-2025 | |
| Si-Bone, INC. | $184.98 | 2021-2024 | |
| Depuy Synthes Sales INC. | $159.39 | 2019-2025 | Monovisc, Orthovisc |
| Forte Bio-Pharma LLC | $128.89 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $99.91 | 2021-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $99.09 | 2024-2025 | Prospera |
| Ferring Pharmaceuticals INC. | $81.03 | 2022-2025 | Euflexxa |
| Merz Pharmaceuticals, LLC | $68.79 | 2024-2025 | Xeomin |
| Arbor Pharmaceuticals, INC. | $68.50 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $60.90 | 2021-2022 | |
| Boston Scientific Corporation | $51.30 | 2025 | General - Pain Management, Intracept |
| Azurity Pharmaceuticals, INC. | $51.06 | 2023-2024 | Horizant, Horizant |
| Allergan, INC. | $34.29 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $33.11 | 2021-2022 | |
| Pfizer INC. | $29.07 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $27.70 | 2022 | |
| Abbott Laboratories | $24.39 | 2022 | |
| Nalu Medical, INC. | $22.50 | 2024 | Nalu Neurostimulation System |
| Lifeward, INC. | $21.43 | 2025 | |
| Spr Therapeutics, INC | $20.90 | 2023 | Sprint Pns System |
| Medtronic, INC. | $20.39 | 2024 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $19.38 | 2023 | Intracept |
| Smith+Nephew, INC. | $15.45 | 2025 | Collagenase Santyl |
| Tersera Therapeutics LLC | $15.22 | 2021 | |
| Mdd US Operations, LLC | $14.99 | 2022 | |
| Microtransponder, INC. | $13.93 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Franco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.